Introduction
H���������o� �� � ���������� �o��o� d������ �� d�v�d�d ���o ������� ��d ���o�d��� ����������o�, of ����� ��� fo���� is more common (1) . Hypertension endangers the health of �d���� ��d ����d���, ��d ������ �����-o���� d�������, ����cially diseases in the cardiovascular system. The disease worsens with time if the patients are not treated properly (2) . H���������o� ������� ���d� �o ����� f������, ��f� v���������� hypertrophy and other complications, which cause significant heart injury, affecting left ventricular diastolic function and result in cardiac dysfunction (3) . The progression of hypertensive heart disease includes myocardial fibrosis and changes in ��f� v���������� ��o�����, ����o�� ����� ��d �����o�� of ����� failure or left ventricular systolic dysfunction before functional changes (4, 5) . Half of the patients with hypertension ��v� d����o��� d��f�����o�, ����� ��� ��ov�d ��o���� ������d to the increasing incidence and morbidity of cardiovascular diseases and the progression of heart failure (6) . Patients with diastolic dysfunction have increased year by year with the high incidence of hypertension and its complications (7) .
H���������o� �� ������� ������d ���� ����o������ �o�v������ enzyme inhibitor (ACEI), angiotensin II receptor antago-���� �ARB�, ������� �����o���� �CCB� ��d β receptor blockers. T���� d���� ��� �����v� ����������v� ��������' ��f� v���������� diastolic function, clinical signs and symptoms (5, 8, 9) . Galectin-3 (Gal-3), which is a member of the galectin family ��d � β-galactoside-binding protein of 30-kDa, plays an important role in immune regulation (10) . As a pathogenic factor of heart failure, Gal-3 not only causes myocardial inflammation and fibrosis and affects left ventricular systolic function, but also promotes cardiac remodeling, myocardial fibrosis and heart failure (11) .
A��o�d��� �o � ���v�o�� ���d�, ���-� �� ��o���� ������d �o ��� d�v��o����� ��d ��o������o� of ���d�ov������� d�������, expected to be a biomarker for assisting the diagnosis and prognosis of cardiac diseases (12) . However, the role of Gal-3 �� ��� d�v��o�����, ��o������o� ��d ��������� of ��������sion complicated with diastolic dysfunction remains unclear. Therefore, GAL-3 expression in patients with the disease was detected in this study to explore the role of Gal-3 in the development, progression and treatment of the disease. This study was approved by the Ethics Committee of The First Affiliated Hospital of Jiamusi University. The subjects ��d ����� f������� ���� ��fo���d ��d �����d � f���� ��fo���d consent form.
Patients and methods

General
Therapeutic methods and efficacy evaluation. P������� �� ��o�� A ���� �o������� ������d, ����� �����d�d ��ok��� �������o�, ����������, ��d����o� of �od��� ����k�, ������ ��d f�� ����k�, and increasing of aerobic exercise. Their myocardial function and blood pressure were monitored in real-time. According to �o�d���o��, ��� �������� ���� ������d ���� ACEI, ARB, CCB ��d β receptor blockers for 3 months, with diuresis, potassium excretion and correction of acid-base equilibrium disorders given at the same time. Adverse reactions during the treatment were observed. ���d���: M��k�d�� �ff����v�: �����o�� ��d ����� d���������d completely, and improvement of cardiac function was grade II. Eff����v�: �����o�� ��d ����� ���� ����ov�d, ��d ����ov����� of cardiac function was grade I. Invalid: Symptoms, signs and cardiac function had no significant change and even worsened.
Echocardiography. �E V�v�d 7 �o�o� ������o��� d�v��� �������� Electric Company) and M3S probe with 2.5 MHz were used for analysis and measurement by specialist physicians in ultrasonic medicine. Subjects were in supine position breathing calmly, and their ECG was synchronously recorded to obtain the stan-d��d ��o-d������o��� ������ of �����o�� of ��� �����, ��d ��� frequency spectrums of valve orifices and pulmonary vein. Left v���������� d����o��� f�����o� ��� d��������d ���� ������� �o mitral valve early peak flow velocity (EPFV), atrial peak flow velocity (APFV), maximum flow velocity ratio of early to atrial d����o�� �EPFV/APFV� ��d ���k ������ ������� v��o���� �E/E').
Detection methods. Five milliliters of fasting peripheral blood was extracted, placed in a vacuum tube free of anticoagulant, and centrifuged at 670.8 x g, at 20-25˚C for 10 min to separate serum. An Elx-800 microplate reader (BioTek) was used to detect ����� ���-� �o���������o�, ���� ����� ������d o�� �� ���o�d���� with the instructions of human Gal-3 enzyme-linked immunosorbent assay (ELISA) kit (Renjie Biotechnology Co., Ltd.). The kit and the sample to be tested were taken out 20 min in advance to balance with room temperature. Sample wells, standard wells and blank wells were set up. The standard wells were added with 50 µl of standard substances with different concentrations, the sample wells were added with 50 µl of the sample to be tested, nothing was added to the blank wells. The wells were added with 100 µl of horseradish peroxidase (HRP)-labeled detection secondary goat anti-human IgG monoclonal antibody (1:250; cat. no. A0201; Beyotime Institute of Biotechnology) (https:// www.beyotime.com/product/A0201.htm), covered with tectorial membranes, and incubated at 37˚C for 1 h. After that, they were �dd�d ���� �50 µ� of �������� �o����o� ��d ���o��d �o ����d fo� 1 min. The liquid in wells was discarded and the wells were dried with absorbent paper. The wells were washed 5 times. Next, the wells were added with 50 µl each of substrates A and B, and incubated at 37˚C for 15 min in the dark. Finally, they were added with 50 µl of stop solution. The Elx-800 microplate reader was used to detect OD values of wells at 450 nm within 15 min, in order to calculate Gal-3 concentration.
Statistical analysis. SPSS 20.0 (IBM Corporation) was used to statistically analyze the data, GraphPad Prism 7 (GraphPad Software, Inc.) to plot figures. Enumeration data were expressed as [n (%)], and Chi-square test was used for comparison of enumeration data between groups. Measurement data were expressed as mean ± standard deviation (mean ± SD), ��d ��d����d��� ������� �-���� ��� ���d fo� �o������o� of measurement data between groups, paired t-test for comparison before and after treatment within groups. Spearman's test was used for correlation analysis. The receiver operating characteristic (ROC) curve was used to plot the diagnostic value of Gal-3 concentration before treatment for efficacy. P<0.05 indicated a statistically significant difference.
Results
Comparison of general information. There was no significant difference between group A and group B in terms of sex, age, history of smoking, history of drinking, place of residence, educational level, fasting blood glucose (FBG), hemoglobin (Hb), red blood cell (RBC) count, platelet (PLT) �o���, ��������� ����o�����f����� �A�T�, ������� ����o�����ferase (ALT), uric acid or serum creatinine (P>0.05) ( Table I) .
Comparison of Gal-3 concentration. I� ��o�� A, ���-� concentration was 7.16±1.63 ng/ml before treatment and 4.37±1.52 ng/ml after treatment. The concentration was 3.26±1.43 ng/ml in group B. Gal-3 concentration in group A was significantly higher than that in group B (P<0.05). After treatment, the concentration in group A was significantly lower than that before treatment (P<0.05), but significantly higher than that in group B (P<0.05) (Fig. 1) .
Correlation of Gal-3 concentration with cardiac function grading in group A. ���-� �o���������o� ��� �����f������� ������ �� �������� ���� ���d��� f�����o� ���d�� II, III ��d IV than that in patients with grade I (P<0.05). The concentration increased with the rise of cardiac function grading. Cardiac f�����o� ���d� I ��� ��� �� 1, ���d� II �� 2, ���d� III �� � and grade IV as 4. According to Spearman's correlation, Gal-3 �o���������o� ��� �o����v��� �o�������d ���� ���d��� f�����o� grading (r=0.569, P<0.001) (Table II and Fig. 2 ).
Comparison of diastolic function indexes.
Co�����d ���� before treatment in group A, patients after treatment had �����f������� ������ EPFV ��d EPFV/APFV (P<0.05), but significantly lower APFV and E/E' (P<0.05). Compared with group B, patients in group A after treatment had significantly �o��� EPFV ��d EPFV/APFV (P<0.05), but significantly ������ APFV ��d E/E' (P<0.05) (Table III) .
Gal-3 concentration before treatment in the effective and invalid groups and its predictive value for efficacy. D����� ���������, ��o�� A ��d 2 �������� ���� ������ ��d 1 ������� with dizziness, none of whom were treated. After treatment, B�fo�� ���������, ���-� �o���������o� �� ��� �ff����v� ��o�� was 6.41±1.73 ng/ml, significantly lower than 9.16±2.37 ng/�� in the invalid group (P<0.05). The ROC curve of Gal-3 concentration before treatment was plotted for diagnosing the efficacy for hypertension complicated with diastolic dysfunction. The AUC of Gal-3 concentration was 0.792 (95% CI, 0.691-0.894), the sensitivity was 73.24% and the specificity was 79.31%, with an optimal cut-off value of 7.68 ng/ml (Table IV and Fig. 3 ).
Discussion
W��� �� ���������� ����d���� �� ������ �����, ����������o� �� an important risk factor for many cardiovascular diseases (15) . Major cardiac changes in patients with hypertension are left v���������� ����������� ��d �������o���, ����� ��� ���d��� causes of cardiac diastolic dysfunction (16) . In the early ����� of ���d��� d����o��� d��f�����o�, ��� �����o�� ��d signs of heart failure are unapparent. However, as the disease ��o�������, �o�� �������� ���� ���d��� d����o��� d��f�����o� ��ff�� f�o� ���o�d��� ����o��� d��f�����o�, �����v���d ����� and symptoms of heart failure (17) . Therefore, it is particularly important to find biomarkers related to the development, ��o������o� ��d ��������� of ����������o� �o��������d ���� diastolic dysfunction. A� � β-galactoside-binding lectin and a member of the soluble protein family, Gal-3 present in the nucleus promotes vascular injury and cardiovascular fibrosis. In patients with heart failure, plasma Gal-3 level has been proven to be the best predictor of short-term prognosis (18) . There are many studies on Gal-3 in hypertension and heart failure. According �o C��v��� et al �19�, ���-� �o���������o� �� ������ of �������� with pulmonary hypertension significantly increases, so Gal-3 ����� �� ���o����� �o�� �� ��� ����o�����o�o����� ��o���� of the disease, and it can be used as a biomarker for reflecting the functional state and disease progression of the disease. A��o�d��� �o ����� et al (20�, ���-� �� ��vo�v�d �� ��� ����ogenesis of cardiac fibrosis which is a leading cause of diastolic dysfunction, so it can be used as a predictor of diastolic Table III . Comparison of diastolic function indexes before and after treatment in group A, and between group A and group B (mean ± SD). .05, compared with the same index before treatment; b P<0.05, compared with the same index after treatment. Gal-3, galectin-3; EPFV, early peak flow velocity; APFV, atrial peak flow velocity; EPFV/APFV, maximum flow velocity ratio of early to atrial diastole; E/E', peak mitral annulus velocity. dysfunction in patients with atrial fibrillation and heart failure. T�� ������� of ���� ���d� ��o��d ���� ���-� �o���������o� �� group A was significantly higher than that in group B, and �o����v��� �o�������d ���� ���d��� f�����o� ���d���; ���� ��, Gal-3 concentration significantly increased with the rise of cardiac function grading. These findings indicate that Gal-3 may be involved in the development and progression of ����������o� �o��������d ���� d����o��� d��f�����o�, ��d �� increases with the aggravation of the disease. This is similar to the findings of previous studies. The pathological process of hypertensive disease progression is myocardial fibrosis (21) . Therefore, Gal-3 as a marker for myocardial fibrosis (22) may ���d����� �������� ���� ��� d�����o����o� of ���d��� f�����o� and the aggravation of myocardial fibrosis. C���������, �������� ���� ����������o� ��� �o��o��� ������d ���� ACEI, ARB, CCB ��d β-receptor blockers, which can control blood pressure, improve cardiac structure and function, and inhibit myocardial fibrosis and the release of inflammatory cytokines. They can also reduce the left ventricle and its cardiac chamber, and improve cardiac diastolic function (23) (24) (25) (26) . In the present study, after treatment, Gal-3 concentration in group A was significantly lower than that before treatment, but significantly higher than that in group B. Although the patients' Gal-3 concentration after ��������� d�d �o� ������ �o �o����, ����� ���d��� d����o��� function was improved. Therefore, the inhibition of Gal-3 concentration may be one of the therapeutic mechanisms. In a study by Calvier et al (27) , the increasing expression of Gal-3 in experimental hyperaldosteronism is related to cardiac and renal fibrosis and dysfunction. Inhibition or blocking of the expression through drugs reduces cardiac and renal fibrosis, so Gal-3 can be used as a new target for pharmacological intervention. According to a study by Vergaro et al (28) , the inhibition of Gal-3 expression and protein content prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice. Therefore, Gal-3 concentration may affect the treatment of the disease. In this study, before treatment, Gal-3 concentration in the effective group was significantly lower than that in the invalid group. According to the ROC curve, Gal-3 concentration before treatment had a high diagnostic value for the clinical efficacy. These findings indicate that Gal-3 concentration before treatment has a predictive value for efficacy.
This study confirmed the role of Gal-3 concentration in ��� d�v��o�����, ��o������o� ��d ��������� of �������� ���� hypertension complicated with diastolic dysfunction, but it still has deficiencies in design. Drugs were given based on the patients' signs and symptoms, so their specific effects on Gal-3 �o���������o� ������ ������� ��d ���k f���o�� �ff������ ��� onset and treatment of the disease were not explored. These deficiencies require further research to support the results of this study.
In conclusion, Gal-3 may be involved in the development ��d ��o������o� of ����������o� �o��������d ���� d����o��� dysfunction. Its concentration increases with the rise of cardiac function grading but significantly decreases after treatment. Therefore, Gal-3 concentration before treatment can be used as a potential predictor of efficacy. Figure 3 . Serum Gal-3 concentration before treatment in the effective and invalid groups and its predictive value for efficacy. (A) According to ELISA, before treatment, serum Gal-3 concentration in the effective group was significantly lower than that in the invalid group (P<0.05). (B) According to the ROC curve, the AUC of serum Gal-3 concentration for evaluating efficacy was 0.792 (95% CI, 0.691-0.894), the sensitivity was 73.24% and the specificity was 79.31%, with an optimal cut-off value of 7.68 ng/ml. * P<0.05. Gal-3, galectin-3; ELISA, enzyme-linked immunosorbent assay; AUC, area under curve; ROC, receiver operating characteristic. 
